Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ400MR)

This product GTTS-WQ400MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ANGPT2 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001118887.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285
UniProt ID O15123
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ400MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1849MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AG1-25
GTTS-WQ13142MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04383119
GTTS-WQ8786MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IBI-306
GTTS-WQ5809MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CFZ-533
GTTS-WQ12092MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ2114MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ12869MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA OPN-305
GTTS-WQ3557MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAX069
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW